The abstract is read at the publisher; the summary is JClub's.
Invasive fungal infections still cause substantial morbidity and mortality despite antifungal therapy, even as first-in-class antifungals and new combination or host-directed strategies advance.
- Why it matters: Current antifungal drugs face pharmacological limits, increasing resistance, and socioeconomic barriers, leaving a major treatment gap for invasive fungal disease.
- What they did: This Review summarizes ongoing clinical research on expanding strategies, including combining systemic antifungal drug classes, adjunctive local antifungal administration, and immune-targeting host-directed therapies.
- The result: The emerging pipeline of novel antifungals and host-directed approaches suggests a turning point for invasive fungal infection management and future treatment optimization.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.